Concepedia

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria G. Olivares, Violeta Sánchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna,

Clinical Cancer Research · 2009 · 131 citations · 45 references

DOIFull text

Open access

Abstract

Inhibition of PI3K and mTOR are required for the growth-inhibitory effect of HER2 antagonists. These findings collectively support the combined use of trastuzumab and mTOR inhibitors for the treatment of HER2(+) breast cancer.

References

45

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.6K citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.4K citations · Full text

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.8K citations

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.3K citations · Full text

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text